Immune-related adverse events of immune checkpoint inhibitors: a review

作者：Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lian Li, Lan Bai, Yuan Bian · 发表于：Frontiers in Immunology · 年份：2023 · DOI：10.3389/fimmu.2023.1167975 · 被引用次数：426 · 研究领域：Cancer Immunotherapy and Biomarkers、Immune Cell Function and Interaction、Lung Cancer Treatments and Mutations

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.